ArticleInternational journal of general medicine2026
Predictive Performance of a Serum sRAGE/sVEGFR-3 Dual-Biomarker Combination for Hypercoagulability Status in Pediatric
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate serum soluble receptor for advanced glycation end products (sRAGE) and soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) as biomarkers for hypercoagulable state in children with Methods: We retrospectively enrolled 352 children with MPP (hypercoagulable, n=98; non-hypercoagulable, n=254). Serum sRAGE and sVEGFR-3 were measured by enzyme-linked immunosorbent assay (ELISA). Spearman analysis, Box-Tidwell test, and restricted cubic splines (RCS) assessed correlations/nonlinear effects; least absolute shrinkage and selection operator (LASSO) regression selected variables; multivariable logistic regression analyzed risk factors (variance inflation factor [VIF] for multicollinearity); receiver operating characteristic (ROC) curve analysis evaluated predictive value (Youden index cut-off); Bootstrap (1000 iterations) validated internally; net reclassification improvement (NRI) and integrated discrimination improvement (IDI) assessed incremental value. Results: Serum sRAGE and sVEGFR-3 were elevated in the hypercoagulable group (both Conclusion: Elevated serum sRAGE and sVEGFR-3 are associated with hypercoagulable state in children with MPP; combined detection may serve as an exploratory reference for early identification, but requires prospective longitudinal and independent multicenter validation for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.